General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RMHEN
ADC Name
PRO-1107
Synonyms
PRO-1107; PRO 1107; PRO1107
   Click to Show/Hide
Organization
ProfoundBio (Suzhou) Co., Ltd.
Drug Status
Phase 1/2
Indication
In total 6 Indication(s)
Breast cancer
Phase 2
Clinical Trial
Endometrial cancer
Phase 2
Clinical Trial
Lung cancer
Phase 2
Clinical Trial
Oesophageal cancer
Phase 2
Clinical Trial
Ovarian cancer
Phase 2
Clinical Trial
Urothelial cancer
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
8
Antibody Name
Undisclosed
Antigen Name
Inactive tyrosine-protein kinase 7 (PTK7)
 Antigen Info 
Payload Name
Monomethyl auristatin E
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Undisclosed
Conjugate Type
Undisclosed
Combination Type
LD343